Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma
Status:
Recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
MiST is a British Lung Foundation funded, University of Leicester Study, a multi-arm
stratified therapy based clinical trial for patients with relapsed mesothelioma.
The goal of MiST is to enable acceleration of novel, effective personalised therapy as a
basis for improving survival outcomes for patients with mesothelioma.
Phase:
Phase 2
Details
Lead Sponsor:
University of Leicester
Collaborators:
BerGenBio ASA British Lung Foundation Clovis Oncology, Inc. Eli Lilly and Company GlaxoSmithKline Merck Sharp & Dohme Corp. Roche Pharma AG The Christie NHS Foundation Trust University Hospitals, Leicester